Gooch & Housego: A 1,230p Cash Buyout Settles the Value Debate — What's Left Is Deal Risk

The most telling detail of a takeover is often buried in paperwork, not headlines. On 1 September, Investec — the broker advising Gooch & Housego — filed a routine Form 8.5 dealing disclosure under Rule 8.5 of the UK Takeover Code, showing it had bought and sold the company's shares for the day. What matters is where those trades priced: between about 1,205p and 1,210p. That is the whole situation in one number — a stock resting a few pence beneath the cash it has been promised, waiting for a deal to close.

Gooch & Housego (AIM: GHH) is a British specialist in precision optics and photonics: infrared lenses, ring-laser-gyro optics, electro-optic crystals, and counter-drone systems sold into aerospace and defense, industrial, and life-science markets. On 16 July 2026, Arlington Capital Partners, a Washington private-equity firm focused on defense and government services, launched a recommended cash acquisition at 1,230p per share, with qualifying shareholders also keeping the 4.9p interim dividend — 1,234.9p in total. The offer values the equity at about and the enterprise at , roughly the 874p closing price the day before the announcement.

What Arlington is paying for

The premium is easier to justify once you look at the order book. In the six months to 31 March 2026, G&H grew revenue 15.5% to £81.9 million and adjusted operating profit 16.9% to £7.2 million behind a record £167.3 million order book that covers nearly the full year of expected sales. Aerospace and defense — 43% of revenue — jumped 51.7% on demand for gyro and infrared optics. The prior full year told a similar story: revenue of £150.5 million, up 10.7%, and adjusted profit before tax of £11.9 million, up 46.8%.

The other side of the valuation is how thin that profit is relative to the price. Even after a strong half, the adjusted operating margin is 8.8%, and the offer works out to roughly 25.9 times adjusted operating profit for the twelve months to March 2026. Life sciences is a drag, with its margin halved to 4.6%, germanium supply constraints temper defense output, and net debt has climbed to £49.8 million including leases, or 1.5 times EBITDA. The strategic franchise — hard-to-replace crystal optics and a defense backlog growing faster than sales — carries the price more than today's cash generation does.

The only question left is completion

For a new investor, the business valuation debate is effectively over. A fixed cash number has replaced it, so the residual opportunity is the distance between the traded price and the offer — and that is a thin spread paid to bear completion risk, not ownership of a cheap asset.

The gates have mostly opened. The substantial US antitrust condition has been cleared, and shareholder meetings were scheduled for 26 August. What remains is typical of a defense-adjacent British target: clearance under the UK's national-security regime, court sanction of the scheme, and the mechanics of delisting from AIM, with completion targeted for the fourth quarter of 2026 and a long-stop of 16 January 2027.

The board's argument for taking the money is a value judgment, not a growth forecast: they cite the certainty of immediate cash versus the costs and share-liquidity burden of staying a small AIM-listed operator through program timing, supply-chain, and market-recovery risk. A holder's calculation has thus moved from "what is G&H worth on its own" to "will 1,234.9p arrive" — and the spread now says the market thinks it will. For anyone who missed the 41% move, the entry is a closing-out trade priced at a full multiple, not a beaten-down asset awaiting a re-rating. The number worth watching is the distance to 1,234.9p, because that gap is the whole of the remaining edge.